The FDA has accepted the NDA for zipalertinib to treat adult patients with locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC.

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

Please provide your email address to receive an email when new articles are posted on . Patients with an eGFR below the 25th percentile of distribution for their age and sex had greater risks for ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

Pediatric patients who lived with a low eGFR longer without dialysis had better odds to receive a preemptive or living donor ...

Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm about to say some things that will not make everyone happy. I would like to comment on a recently published article in The New England Journal ...

Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...

Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...

GFR slope predicts kidney outcomes in IgA nephropathy beyond static measures. Learn how this could refine trials and risk ...

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside a genetic amplification found in more than half of glioblastoma tumors, ...